Thought Leaders in Artificial Intelligence: Florian Eggenschwiler, Chief Product Officer of Xovis (Part 1)

A fascinating conversation about how Xovis is applying AI to modeling human behavior in public spaces.

Sramana Mitra: Let’s start by giving our audience a bit of your background as well as the background of the company.

Florian Eggenschwiler: I’m the Chief Product Officer at Xovis. Xovis is a Swiss-based company helping the world rethink people flow. We do that by deploying our own 3D sensors that understand people’s movement. Then we have a variety of software applications that make sense of this data to help a variety of industries to understand how people move through our physical world and initiate change to optimize the flow of people.

Featured Videos

Thought Leaders in Artificial Intelligence: Starmind CEO Marc Vontobel (Part 5)

Sramana Mitra: You have chosen certain markets to go after. What’s happening in the broader ecosystem that you’re playing in with the same kinds of applications and use cases but in different geographies or maybe different use cases. Who is playing in your space that you’re watching from the corner of your eye?

I’ve seen the solution that you’re describing. Today, AI is at its most mature state. I still remember companies that I saw in exactly the same application, but they failed. Timing is a big deal. For you, this is good timing. Who are the other players in your space that you are watching?

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 3)

Sramana Mitra: Talk about your business model. Your doctors are your end customers?

Sungwon Lim: Yes.

Sramana Mitra: Is it a subscription service or a diagnostic model?

Sungwon Lim: We charge per service order. Our customers are hospitals and veterinarian oncologists. We sell our service to them and they add their own margin to the pet owners. Pet owners are usually the payers. We are B2B.

Video FAQs

576th Roundtable for Entrepreneurs Starting NOW: Live Tweeting by @1Mby1M

Today’s 576th FREE online 1Mby1M Roundtable For Entrepreneurs is starting NOW, on Thursday, May 26, at 8 a.m. PDT/11 a.m. EDT/5 p.m. CEST/8:30 p.m. India IST. CLICK HERE to join. PASSWORD: startup  All are welcome!

576th Roundtable for Entrepreneurs Starting in 30 Minutes: Live Tweeting by @1Mby1M

Today’s 576th FREE online 1Mby1M Roundtable for Entrepreneurs is starting in 30 minutes, on Thursday, May 26, at 8 a.m. PDT/11 a.m. EDT/5 p.m. CEST/8:30 p.m. India IST. CLICK HERE to join. PASSWORD: startup  All are welcome!

Alteryx Builds on Trifacta Acquisition to Target Enterprise Sales

According to an IDC report, the global data analytics market is expected to grow from $65 billion this year to over $110 billion by 2025. Data science and analytics platform provider Alteryx’s (NYSE: AYX) recently announced impressive quarterly results. The company Is stepping up its focused sales approach to drive the adoption of its products within the larger enterprise segment.

Thought Leaders in Artificial Intelligence: Starmind CEO Marc Vontobel (Part 4)

Sramana Mitra: Bottomline is, you’re talking about narrowing the market down more and more to figure out where you want to penetrate the market and where you really want to build the business. Then there are sales channel issues. You have to put Salesforce going after each other’s markets. Let’s get to the technology side of what you’re doing. What datasets are you working with? Let’s take the pharma use case.

Marc Vontobel: There’s always a certain set of tools focused on the use case itself. In R&D, for example, we often see some kind of application that manages the new patterns that people are working on. That’s a very good source for us to learn.

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 2)

Sramana Mitra: What is the dataset? Across all these categories, how many drugs and treatments are we talking about that you have modeled and have data for?

Sungwon Lim: Our first service which we commercialized last year is for dog blood cancer. What we are trying to do is help doctors make decisions. The 16 drugs that are used for lymphoma and leukemia are being tested on our platform. We collect the real-world actual treatment cases and provide our reports today.